Drugs / CBD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05670353 | Jan 2023 → Sep 2024 | endometriosis, pelvis syndrome | University of Sao Paulo | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBD | “CBD 10 mg (up-titrated until 150mg or adverse effects) daily for 9 weeks” NCT05670353 ↗ |
| Route | Oral | “will be given orally starting at 10 mg daily” NCT05670353 ↗ |